• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For DENTSPLY SIRONA (XRAY) Could Change Following Its Shift Into Russell 2000 Indices

    Simply Wall St·07/10/2026 02:22:27
    Listen to the news
    • On 27 June 2026, DENTSPLY SIRONA Inc. was removed from the Russell 1000 and Russell Midcap indices and their value counterparts, while being added to the Russell 2000, Russell 2000 Value, and Russell 2000 Dynamic indices.
    • This index migration shifts DENTSPLY SIRONA into a smaller-cap, value-oriented benchmark universe, which can alter how both passive and active investors view the stock.
    • We’ll now examine how DENTSPLY SIRONA’s move from large- and mid-cap indices into Russell 2000 benchmarks may reshape its investment narrative.

    Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

    DENTSPLY SIRONA Investment Narrative Recap

    To own DENTSPLY SIRONA today, you need to believe that its investments in digital dentistry, cost efficiency, and global distribution can eventually turn persistent losses into sustainable profitability. The shift from the Russell 1000 and Midcap indices into the Russell 2000 family does not change that core thesis, but it does highlight ongoing execution risk, especially around reigniting revenue growth and absorbing rising tariff and cost pressures in the near term.

    Among recent announcements, the Q1 2026 results are most relevant here: sales were essentially flat at US$880 million, but the company reported a net loss of US$10 million. That mix of top line stability and continued red ink is important context for the index move, as it underlines why some investors still see earnings recovery and margin improvement as the key catalyst, while others remain focused on the risk of prolonged underperformance if growth and cost actions do not gain traction.

    Yet beneath the index reshuffle, there is a risk around sustained U.S. sales weakness and elective procedure softness that investors should be aware of...

    Read the full narrative on DENTSPLY SIRONA (it's free!)

    DENTSPLY SIRONA’s narrative projects $3.8 billion revenue and $189.7 million earnings by 2029. This requires essentially flat yearly revenue and a $817.7 million earnings increase from -$628.0 million today.

    Uncover how DENTSPLY SIRONA's forecasts yield a $13.40 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    XRAY 1-Year Stock Price Chart
    XRAY 1-Year Stock Price Chart

    While the baseline view focuses on long term digital and cost efficiency catalysts, the more cautious analysts see the index move as fitting a weaker story, with flat US$3.7 billion revenue and only US$95.9 million earnings by 2029, reminding you that opinions can diverge sharply.

    Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth over 3x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

    Ready For A Different Approach?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.